Background Among human immunodeficiency virus (HIV)-infected youth, the role of renal disease (RD) and its management has become increasingly important as these children/ adolescents mature into young adults. The identification of predictors of abnormal renal laboratory events (RLE) may be helpful in the management of their HIV infection and its associated renal complications. Methods Data collected from HIV-infected youth followed for ≥48 months were analyzed to identify predictors of resolution versus persistence of RLE and determine the utility of RLE to predict the onset of RD. Analysis included descriptive and inferential methods using a multivariable extended Cox proportional hazards model.
Introduction
Renal disease in human immunodeficiency virus (HIV) type 1 (HIV-1)-infected children and adolescents may occur as a result of the complications of HIV-1 infection and as well as from highly active antiretroviral therapy (HAART) [1] [2] [3] [4] [5] [6] . Treatment-dosing guidelines and new drug development have evolved over the years, resulting in exposure to antiretroviral agents from an increasing number of different classes of patients for prolonged periods of time. Indeed, children and adolescents who acquired HIV infection perinatally or early in life as a result of parenteral or sexual exposure generally start HAART earlier in the course of their disease and are maintained on HAART for most of their lives [7] . HIV-associated nephropathy (HIVAN) was recognized previously as the leading cause of chronic kidney disease (CKD) in adults and children with HIV in the USA [8] [9] [10] . In 2004 nearly half of the cases of CKD in HIV-infected patients were reported as being due to HIVAN. Since then, however, the spectrum of CKD in HIV-infected patients has been changing, with fewer cases of HIVAN and an increasing number of cases of comorbid kidney disease, such as that caused by hypertension and diabetes, being reported [11] [12] [13] [14] . Recently, the Medical Monitoring Project of the Centers for Disease Control and Prevention (CDC) [15] reported an association between renal disease and longer duration of HIV infection. Given the number of recent reports linking nephrotoxicity with certain antiretroviral agents and the length of such therapy in children, it is possible that among HIV-infected youth HAART may increasingly contribute to the development of CKD.
The data reported here are from a retrospective analysis of HIV-1-infected children in the USA enrolled in the Pediatric AIDS Clinical Trials Group Protocol 219/219C (PACTG 219/ 219C). In the initial report on this cohort, Andiman et al. [6] described the incidence of renal laboratory abnormalities or renal laboratory events (RLEs), which was defined as the last measured value in a sequence of a minimum of three abnormal values in at least one of the following categories: serum creatinine (Cr), urine persistent proteinuria (PP), and estimated glomerular filtration rate (eGFR). Twenty-two percent of the PACTG 219/219C cohort had at least one persistent RLE which was associated with older age, black race, Hispanic ethnicity, use of nephrotoxic antiretroviral drugs (tenofovir and indinavir), and use of other nephrotoxic antimicrobial agents previously known to be associated with these RLEs. Subsequently, Purswani et al. [16] reported kidney biopsy findings in the same cohort and described both demographic and clinical risk factors for children with HIV-associated CKD. In the study reported here we extended these previous findings by determining the sensitivity and specificity of RLEs for new renal disease diagnoses as markers of new onset renal disease. We also attempted to identify predictors of resolution versus persistence of RLEs in children with HIV infection followed-up in the P219/219C study.
Methods

Study population
PACTG 219/219C was a multicenter prospective cohort whose main objective was to determine the consequences of HIV-1 infection and its treatment from infancy through childhood into adolescence. The study opened to enrollment in May 1993 and spanned what is now accepted as the pre-HAART era from 1993 to 1997 and the HAART era, from 1998 to May 2007 [7] , when it ended. Details of Protocol 219/ 219C have been previously described [6, 16] . Children enrolling at or after January 1, 1998 were considered to have enrolled during the HAART era.
Participants in the study reported here were a subset of the 2,102 subjects reported by Andiman et al. [6] who had no abnormal laboratory findings or renal diagnosis at study entry. In this study, we defined abnormal RLEs as the first measured value in a sequence of a minimum of three abnormal values in at least one of the following categories: serum creatinine (Cr), urine persistent proteinuria (PP), or estimated glomerular filtration rate (eGFR). The date of onset of the abnormal RLE was the date of the earliest abnormal laboratory value, across categories. The timing definition used here contrasts with that used in Andiman et al. [6] , where the timing of the RLE was also the earliest date across categories, but within a category the third rather than first sequential laboratory abnormality defined onset. Cutoff for increased urine protein excretion by urinary dipstick was trace or greater, while cutoffs for increased Cr were age-adjusted [14] and that for reduced eGFR was <60 mL/min/1.73 m 2 . The modified Schwartz-CKID formula was used to compute eGFR for those aged less than 18 years [17, 18] and the Modification of Diet in Renal Disease (MDRD) formula was used for those over 18 years of age [19] . The requirement for three sequential abnormal results in the urine protein dipstick analysis minimized the possibility that a concomitant fever or infection was the cause of the abnormality.
Definitions of study outcomes
Renal laboratory outcomes
The following renal laboratory outcomes were determined:
Resolution of RLE: Study participants who were identified with a RLE and for whom there were subsequently at least three sequential normal laboratory values in the given category. If abnormalities occurred in more than one domain, each had to resolve to meet this definition. The date of resolution was the latest of the three normal values, across categories. Persistence of RLE: Study participants who were identified with RLE and in whom there was no resolution of abnormal measures were considered to have persistent RLE. New onset renal diagnosis: Any subject with a RLE in whom there was no renal diagnosis at P219C study entry, but who subsequently received a specific renal diagnosis was considered as having a new onset renal diagnosis. Renal-related death: Death of a participant in whom renal disease was either a primary cause or co-existing contributing cause of death. Renal-toxic HAART: Medications recorded in the P219/219C database were considered in this analysis if they met the definition of renal-toxic medications as defined in Andiman et al. [6] . HAART regimens which included either tenofovir (TDF) or indinavir (IDV) were considered to be renal-toxic.
Only participants who had been in the study for at least 48 months were included in the analysis in order to allow sufficient additional time (18 months) for a patient who previously had an RLE during the first 30 months of the study to experience a resolution (3 sequential normal laboratory values).
Renal diagnoses
Clinical renal diagnoses were coded using the Medical Dictionary for Regulatory Activities (MedDRA®) v14.1, a hierarchical and multiaxial medical coding terminology for clinical events. Queries for renal events were done broadly using Preferred Terms associated with the renal and urinary system organ class (SOC). We also identified conditions using the Standardized MedDRA Queries (SMQ), the acute renal failure SMQ, the hypertension SMQ, and the renovascular disorders SMQ. SMQs are predefined sets of related Preferred Terms.
Diagnoses were classified into broad types of renal problems (primary renal, other renal, urinary tract infections, hypertension, renal laboratory abnormalities, edema, hematuria). The earliest occurring episode was selected for further analysis. Information on participant deaths was identified in the source P219/219C database via the death case report form which collected death dates and major and contributing causes, among other information.
Statistical analysis
Selected sensitivity and specificity analyses included the full study population (N = 21,02). The remaining analyses considered only those participants who experienced RLEs. Medication exposures were classified according to whether they occurred at or prior to the date of the RLE or after this time. Medication exposures after RLE resolution were not considered in the analysis. We classified children by their exposure status before and after a RLE.
We compared personal and HIV disease laboratory markers for participants who enrolled in P219/219C in the pre-HAART era to those for participants who enrolled in the HAART era using standard statistical tests as appropriate: Fisher's exact test, Pearson chi-square test, and the Wilcoxon rank sum test. We next explored the association between each medication exposure and RLE resolution with a Pearson chisquare test, classifying outcomes according to whether participants with exposure to medication at or prior to their RLE were switched off medication after the event. We also computed the sensitivity, specificity, and positive and negative predictive values for the RLE, as well as its persistence in predicting primary renal diagnoses.
Finally, we fit multivariable extended Cox proportional hazards models to explore the associations between the resolution of the RLE and changing medication exposure during the course of the study, adjusting for personal (age at renal event, race, ethnicity, sex) and clinical characteristics (e.g., CDC HIV stage at P219/219C study entry, HIV viral load, and CD4 percentage). Study time began at the RLE and ended at either its resolution or censor (last study visit). HIV disease markers were considered in these models separately as they changed over time and as they were measured at the RLE (defined as the closest value at or before the time of the RLE). In addition to considering the continuous values of CD4 percentage and HIV RNA viral load, we also used categorical values by classifying CD4 percentage using a cutoff of 25 % and HIV RNA viral load using a cutoff of 100,000 copies/mL.
We used a two-step modeling process. In the first step, we explored the univariable associations between covariates and RLE resolution. We then built a core multivariable model by including univariable covariates with a p of<0.20, retaining only those factors with adjusted p<0.15. In the second step, we explored the associations between changing medication use and RLE resolution after adjusting for the core model variables. Each model included a separate medication exposure. Time-dependent HIV markers (viral load and CD4 percentage) were the most recent values prior to the start of the interval for which changes in medication were reported. We performed secondary sensitivity analyses, focusing only on the association between these markers and RLE resolution. Finally, analyses were performed on the subset of participants who enrolled into P219/219C during the HAART era. The statistical program SAS v9.2 (SAS Institute Inc., Cary, NC) was used for the analyses, and values with two-sided p<0.05 were considered to be statistically significant. Figure 1 depicts a flow chart showing the breakdown of the 1,874 participants who met the study criteria at entry and the distribution of those children who subsequently developed a renal lab abnormality or event (RLE) or who a new renal condition (diagnosis). On study entry, the majority of the 1,874 children (1,734, or 93 %) were perinatally infected, and 428 of the 1,874 children subsequently had a new RLE in terms of Cr, PP, or eGFR. All but 15 of these 428 children were perinatally infected (96 %).
Results
Study population
Of the 428 subjects with a new RLE, 199 resolved their RLE while 229 did not. Among those 229 who had persistent RLE, 35 (15.3 %) developed a new renal diagnosis. There were eight deaths in this latter group, of whom four died of renal-related causes. There were an additional eight deaths in the group without new renal diagnoses; none of these latter deaths were renal related Among the 199 children with resolution of their abnormalities and the 1,446 children who did not develop any new RLE, there was a much smaller percentage of children [2.5 % (5/199) and 2.7 % (39/1446), respectively] who developed a new renal diagnosis. Among the 1,446 children who did not develop any new RLE, six of the 39 children with a new renal diagnosis died-three of renal-related causes; 42 of the other 1,407 children died, with only one death being renal-related. This latter renal-related death was counted as a "new renal diagnosis" for the purposes of the sensitivity/specificity analysis. There was one non-renal-related death in the group of 199 who showed resolution of the RLE. HIV-associated nephropathy, and chronic renal failure were cited as the cause of death in the majority of those children whose deaths were renal related. Two children died with acute renal failure. The greater majority of children whose deaths were not renal related died of common acquired immune deficiency syndrome (AIDS)-related complications (i.e., pneumocystis pneumonia, wasting, HIV encephalopathy, etc.).
The frequency and severity of the new renal diagnoses were more pronounced among those children who had persistent abnormalities. While the frequency of renal tubular disorders was only minimally increased among children with resolution of their RLE (1/199, 0.5 %) compared to children with persistent RLE (4/229, 1.7 %), the frequency of proteinuria, renal parenchymal disease, and renal failure were all markedly higher among children who had persistent RLE. In each of these three categories, the percentage of children who Fig. 1 Impact of persistent or resolved renal laboratory abnormalities on the development of new renal disease conditions (diagnoses). The flow chart depicts the outcome in the development of a new renal diagnosis based on renal laboratory screening tests that persist or resolve. At study entry, the study cohort comprised 1,874 children with no renal laboratory abnormalities or renal diagnosis. During the follow-up, 428 (23 %) children developed new renal laboratory-proven abnormalities and 1,446 (77 %) did not. Of those 428 cases with new renal laboratory abnormalities, 229 (54 %) showed persistence of abnormal values for the laboratory renal studies, with 35 children (15.3 %) developing a new renal diagnosis. In contrast, 199 (46 %) of these 428 children showed resolution of their abnormal renal studies, with only five (2.5 %) developing a new renal diagnosis. In the 1,446 (77 %) children who never developed new renal laboratory abnormalities, there were 39 (2.7 %) who developed a renal diagnosis had persistent RLE was at least fivefold higher than that among children who experienced resolution of their RLE. Seventeen (7.4 %) of the children with persistent RLE developed a renal parenchymal disease, with 11 children developing nephrosis, and two children each developing focal segmental glomerulosclerosis, glomerulonephritis, and lupus nephritis, respectively.
Demographic and clinical characteristics
The demographic and clinical characteristics of the 428 participants in the analysis who had three consecutive RLEs are given in Table 1 which compares those enrolled in the pre-HAART era to those enrolled during the HAART era. Participants enrolled during the HAART era were slightly older at the time of the RLE and were followed (to resolution/last visit date) for a shorter period of time than those enrolled during the pre-HAART era. As expected, there were fewer deaths among those enrolled during the HAART era. Overall, about 46 % of the participant achieved resolution of their RLE. The number of participants who achieved resolution of their RLE was similar in both subgroups. Both CD4 percentage and HIV RNA viral load values indicate that HAART-era participants were healthier at the time of their RLE than were those enrolled prior to the HAART era (all p<0.05). It should be noted that 84 participants, primarily among those enrolled during the pre-HAART era, had no HIV RNA viral load measured at the time of the RLE.
Sensitivity and specificity of renal lab events for new renal diagnoses Figure 2a depicts the respective values for sensitivity, specificity, and positive and negative predictive values for an abnormal RLE for predicting a new renal diagnosis in children in the source population (1, 874) . Figure. 2a depicts these same values, but for persistent abnormal RLE for predicting a new renal diagnosis among children who developed a new RLE (N = 428). The sensitivity of RLE for predicting a new renal diagnosis for all children in the source population was only 50 %, while the specificity for ruling out renal disease was high (78 %). In contrast, the sensitivity of persistent RLE for predicting a new renal diagnosis among the 428 children with new onset of RLE was high (88 %) while the specificity of IDV, Indinavir; TDF, tenofovir; HAART, highly active antiretroviral therapy; RLE, renal laboratory events a Switched off, Medication exposure before RLE but not after; Switched on, medication exposure after RLE but not before; Always exposed, medication exposure both prior to and after RLE; Never exposed no medication exposure prior to end of follow-up or RLE resolution. Exposure status considered until resolution, in cases where RLE resolved, or to end of follow-up b Chi-square test those children with RLE, persistence of RLE captured almost 90 % of those with renal diagnoses, while among all children in the source population, the presence of an RLE identified about half of those with renal diagnoses.
Medication exposures
In the total group of 428 participants, 88 % of the children enrolled during the HAART era were exposed to HAART prior to the onset of their first RLE as opposed to 61.5 % of those enrolled during the pre-HAART era (p<0.001, Fisher's exact test), but this was likely due to the ready availability of HAART during the latter time period. There was no statistical difference related to the timing of exposure to renal-toxic HAART between children who enrolled during the two eras, with 20 % of HAAR T-era participants receiving renal-toxic HAART prior to the RLE compared to 14 % of pre-HAART-era participants (p=0.11). Similarly, for the other classes of medications, exposure timing for HAART-era and pre-HAART-era participants did not differ.
When we analyzed the timing of medication exposure and resolution outcome, the statistical results were heavily weighted by the number of subjects never exposed to the medications (Table 2) . We then focused on those study participants receiving medications prior to the time of the abnormal RLE, crossclassifying outcomes according to whether or not they were still exposed after the RLE. While there was resolution of the RLE among 46 % of those participants on continuous HAART, 55 % of patients never treated with HAART also experienced resolution (p=0.05) ( Table 2 ). There is no evidence for increased rates of resolution when renal-toxic regimens were stopped. For example, of those participants who no longer were exposed to renal-toxic HAART after the RLE, 30 % resolved the RLE as compared to 29.8 % of those subjects who still remained on that class of medication. When this analysis was performed using hierarchical and mutually exclusive classification of medication exposure prior to the RLE (if they had any exposure to renaltoxic HAART and, if not, another HAART regimen, a non-HAART antiretroviral regimen, or no exposure to any antiretroviral agent), there was a suggestion that a lower resolution rate was associated with early renal-toxic HAART exposure (30 %) as compared to the rate for those exposed to other antiretroviral regimens (50 %; p=0.03).
Time to resolution of abnormal renal lab events Table 3 shows, for the youths with renal laboratory abnormalities, the association between medication exposures and resolution, adjusting for time-varying CD4 percentage, CDC stage C and Black race (HIV RNA viral load measurements as they changed over time did not meet the core model inclusion criteria). None of the medication exposures (renal-toxic HAAR T, TDF, IDV, or non-antiretroviral renal-toxic concomitant medications) were significantly associated with RLE resolution (p ≥ 0.53; results repeated as analysis set 1 of Table 4 ). We repeated the modeling process to adjust for CD4 percentage (<25 %), and HIV RNA viral load (>100,000 copies) at the time of the first RLE (Table 4 , analysis set 2). In addition to Black race and CDC Stage C, only HIV RNA viral load met the model inclusion criteria. There were no significant associations between medication exposures and resolution (p>0.35). Since many participants were missing viral load data, we next developed a core model adjusting only for CD4 percentage measured at the time of the RLE. No other core model covariates met the inclusion criterion. There were no significant associations with medication exposure (p>0.63; Table 4 , analysis set 3). Results for core model covariates suggested reduced rates of resolution for youths with CDC Stage C disease classification (p<0.10), low time-varying CD4 percentage (p=0.06), higher HIV RNA viral loads at RLE (p=0.01), and low CD4 percentage at RLE (p=0.002) ( Table 5 ). There were also no significant associations with medication exposure when we analyzed only the participants enrolled during the HAART era (p>0.24; data not shown). For these participants, older age at the RLEs was associated with a longer time to RLE resolution (p=0.02; data not shown).
Results of a sensitivity analysis focused solely on the relation between resolution and each CD4 percentage and HIV RNA viral load measures (Electronic Supplementary Material Table 1 ) confirmed the reduced resolution rates for youths with low CD4 percentage and high HIV RNA viral loads. Additional analyses also confirmed the association between CDC Stage C disease classification and reduced resolution (p<0.10; data not shown). In the sensitivity analysis of the HAART era-enrolled participants, the only significant findings were the association between older age at first RLE and reduced resolution rates (p=0.01; data not shown).
Discussion
Recent data have suggested that HAART can change the natural history of HIVAN, not only by preventing its development but also by halting its progression once developed [11, 12] . While the time-to-event analysis did not directly address the impact of non-renal toxic HAART on resolution of RLE, the descriptive analyses appeared to indicate that HAART had little impact on RLE resolution. We attempted to determine whether there is any association between persistent RLE and the use of renaltoxic HAART (as suggested recently by Leal et al. [20] ). We once again found little evidence for a relationship between medication exposure and resolution of abnormal RLEs. What this study did show, however, was that low CD4 percentage values, higher HIV RNA viral load values, and older age at the time of the RLE were all associated with reduced rates of RLE resolution. A possible explanation is that patients with advanced HIV disease might have severe renal disease that does not respond to HAART. Since our analysis encompassed both the pre-HAART and HAART eras, data from the sicker children of the pre-HAART era is likely driving these findings. Nevertheless, some individual findings from our unadjusted, descriptive analyses suggest that continued exposure to renal-toxic HAART may be associated with persistent RLE. The sensitivity and specificity analyses showed that three sequential abnormal renal laboratory values were only modestly effective in predicting the occurrence of new primary renal diagnoses in HIV-infected children and adolescents. With respect to those participants with an existing RLE, it is noteworthy that persistence of these abnormal renal laboratory valuess was a good screening measure for these same outcomes. Overall, the negative predictive values of these two assessments were high. Therefore, absence of RLE was a good indicator to rule out renal diagnoses, as would intuitively be expected. This result suggests that when screening HIV-infected children and adolescents for renal disease, persistence of any of these three renal laboratory abnormalities should prompt referral to a nephrologist for a more thorough evaluation.
One limitation of our analyses was that PACTG 219/219C was not designed specifically to study HIV-renal-related disease; consequently, all renal-related data collection was done as part of the child's continuing care and not mandated prospectively as part of the study design. Nor did it include screening for micro-albuminuria or determining the microalbumin/Cr ratio. Despite these limitations, we have previously published two papers describing the nature of HIV-related renal disease using this same dataset [5, 6] . A second limitation was that some of our retrospective analyses divided the total number of study subjects into two subgroups: those children enrolled in P219/219c during the pre-HAART era (1993) (1994) (1995) (1996) (1997) versus those enrolled during the HAART era (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . The children enrolled during the pre-HAART era continued to be followed-and data collected-during the latter period when they were being treated with HAART. Hence, the results from this group may have been biased by the effects of untreated HIV infection prior to the time the children started HAART. There are two additional limitations to our analysis. Firstly, we did not specifically assess for the potential nephrotoxic effects of either ritonavir-boosted atazanavir or lopinavir, as suggested recently in a report by Ryom et al. [21] based upon data from adult patients enrolled in the D:A:D study (Data Collection on Adverse events of Anti-HIV Drugs Study). Secondly, our analysis included data collected only through to 2007. Hence, our results may have been influenced by the fact that only 20 % of the cohort in the HAART era were exposed to either TDF or IDV.
Based upon recent data from adults, it is probable that the nature of HIV-associated renal disease is changing. The frequency of HIVAN may be decreasing as a result of the widespread availability of HAART, which may be preventing the development of the early stages of HIVAN. At the same time there is a greater recognition of the potential nephrotoxicity of various antiretroviral agents which may be a concern among younger HIV-infected children whose renal function is still maturing. The difficulty here relates to how to distinguish the effects of the virus from the effects of the drugs. While proteinuria, especially PP, is a laboratory hallmark of HIVAN; additional laboratory abnormalities, including alterations in serum Cr, eGFR, or other electrolyte abnormalities, may be secondary to the effects of HIV or the medications [22] . The ability to discern the etiology of abnormal RLEs may be especially difficult in those patients who have more advanced HIV disease and are being treated with HAART (especially if they are on nephrotoxic HAART). This possibility may have influenced our results. Approximately 25 % of the total group of children had AIDS (CDC Class C) at entry, while 39 % had a CD4 percentage of <25 % at or prior to the first RLE. The median age of the entire group at the first abnormal laboratory measure was 10.5 years; hence, many of these children had been infected for at least a decade.
In summary, we analyzed 14 years of prospectively collected data from 1,874 HIV-1-infected youth enrolled in PACTG 219/219C. We were able to document that persistent abnormal renal laboratory values are associated with an increased frequency and severity of primary renal diagnoses and that advanced HIV renal disease is more likely to result in a lack of resolution of RLEs with HAART. Although the sensitivity and specificity analyses show that three sequential abnormal renal laboratory measures alone were only modestly effective in predicting primary renal diagnoses, in those participants with RLEs, the persistence of these RLEs was a good predictor of these same outcomes. The negative predictive values of these same two assessments were also high.
